ClinicalTrials.gg
Active, not recruitingNCT06245772CARBURUpdated Sep 10, 2026

CARegiver BURden, Effectiveness and Other Health Care Measures on Functional Disability, in Patients Treated With Abobotulinumtoxin A for Upper Limb Spasticity

An observational study in Upper Limb Injury, sponsored by Ipsen. Active, not recruiting at 27 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Ipsen · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
113
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to perform, in real world clinical practice, a three-dimensional assessment from patient's, caregiver's and physician's perspectives, of the impact of AboBoNT-A on caregiver burden, functional disability and other health care measures in patients affected with ULS due to acquired brain injuries.

02

Conditions studied

  • Upper Limb Injury

Browse trials for

03

In context

Arm Injuries

64 studies on the registry are indexed under Arm Injuries; 11 are open to participants now.

This study's planned enrollment of 113 is above the median of 101 across 16 observational studies indexed under Arm Injuries.

Browse Arm Injuries studies →

Lead sponsor

Ipsen is the lead sponsor of 290 studies on the registry; 18 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with ULS who will start AboBoNT-A treatment in upper limbs as part of routine clinical practice should be recruited. Patients who received BoNT-A injections in upper limbs less than one year prior to inclusion should not be included in the study. Patients who previously received BoNTA injections in body parts other than upper limbs could be included in the study, regardless of injection anteriority.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient is able to comply with the protocol;
  2. Male and female patients who are at least 18 years old;
  3. The patient is supported by an identified caregiver (family member or other nonpaid adult

    - if the patient has more than one caregiver, the main caregiver will be selected) who provides daily supervision or direct assistance to the care recipient;

  4. The patient has been diagnosed with ULS due to non-progressive acquired brain injuries (stroke, traumatic brain injury, surgical resection of non-progressive tumours, other) or due to non-progressive spinal cord injury with stability of spasticity of the upper limbs;
  5. The decision to treat the patient with AboBoNT-A by the care provider will be made prior to, and independently from the decision to enrol the patient in the observational study;
  6. The patient is covered by a healthcare insurance;
  7. The cognitive and health status of the patient is compatible with the participation to the study.

For Caregivers :

(8) The caregiver is able to comply with the protocol; (9) Male and female caregivers who are at least 18 years old; (10) The cognitive and health status of the caregiver is compatible with the participation to the study.

Exclusion criteria

Exclusion Criteria:

  1. to BoNT-A treatment;
  2. Previously treated with BoNT-A in upper limbs within the last 12 months;
  3. Patients and if applicable Legally Authorized Representative (LAR) of patient under curatorship or deprived of liberty who are opposed to their data collection
  4. Caregivers who are opposed to their data collection;
  5. Caregivers already included for another patient;
  6. Current participation in any other interventional clinical study or have participated within the 12 weeks prior to the inclusion visit;
  7. Non-ambulatory patients except for those who have been hospitalized for the purpose of their BoNT-A injection (maximum length of stay as per clinical judgment of the investigator);
  8. Vulnerable patients (i.e. pregnant and/or lactating women, children, patient under curatorship or deprived of liberty).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
113 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change from baseline in the 5-item Carer Burden Scale (CBS) mean score

    The 5-item Carer Burden Scale is 5-point Likert scale ranging from 0 (no difficulty) to 4 (cannot complete the task), so that higher scores indicate greater burden.

    Time frame: From baseline to 8 weeks

Secondary outcomes

  1. Patient's demographic data

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  2. Caregiver's demographic data;

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  3. Aetiology of spasticity;

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  4. Affected upper limb

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  5. Ascribed spastic muscle group(s);

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  6. Time since onset of the aetiology of upper limb spasticity (ULS)

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  7. Associated lower limb spasticity (LLS)

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  8. Global autonomy evaluation (modified Rankin Scale).

    Patient's Characteristics

    Time frame: through study completion, an average of 14 months

  9. Total dose injected in ULS per cycle;

    Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.

    Time frame: through study completion, an average of 14 months

  10. Dose per muscle group;

    Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.

    Time frame: through study completion, an average of 14 months

  11. Number of injected muscle group(s)

    Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.

    Time frame: through study completion, an average of 14 months

  12. Injections Practices - Total dose injected per cycle (any indication);

    Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.

    Time frame: through study completion, an average of 14 months

  13. Time between two injections;

    Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.

    Time frame: through study completion, an average of 14 months

  14. Criteria for reinjection;

    Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.

    Time frame: through study completion, an average of 14 months

  15. Reasons for treatment discontinuation, if any, and subsequent therapy if any.

    Injections Practices; over a period of 3 cycles of treatment with AboBoNT-A in patients affected with ULS.

    Time frame: through study completion, an average of 14 months

  16. Change from baseline in Carer Burden Scale (CBS)

    Caregiver Burden; The impact of treatment on the physical burden of the caregiver will be assessed by the same caregiver using a modified paper version of the CBS self-administered questionnaire

    Time frame: through study completion, an average of 14 months

  17. Change from baseline in ZBI-12 total score to the end of each AboBoNT-A cycle

    Treatment Effectiveness; ZBI-12 is a self-administered questionnaire for measuring caregiving burden

    Time frame: through study completion, an average of 14 months

  18. Goal score

    Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals

    Time frame: through study completion, an average of 14 months

  19. Goal score change

    Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals

    Time frame: through study completion, an average of 14 months

  20. Distribution of Goals each AboBoNT-A cycle;

    Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals

    Time frame: through study completion, an average of 26 months

  21. Proportion of patients "attaining" the primary Goal

    Treatment Effectiveness

    Time frame: through study completion, an average of 14 months

  22. Proportion of patients "attaining" at least one Goal

    Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals

    Time frame: through study completion, an average of 14 months

  23. Proportion of patients "attaining" the pre-defined goal

    Treatment Effectiveness; To assess goals achievement it will be used an adapted scale / Therapeutic Goal Attainment Scaling (TGAS) with pre-defined goals

    Time frame: through study completion, an average of 14 months

  24. Change from baseline in Modified Ashworth Scale (MAS) score.

    Treatment Effectiveness; Based on routine clinical examination, group muscle tone assessments performed by the Investigator according to the MAS will be recorded

    Time frame: through study completion, an average of 14 months

  25. Change from baseline in SQoL-6D total score

    Patient's Spasticity-Related Health Status (PS-RHS); The SQoL-6D consists of a 6-dimensions self-administered questionnaire that provides an overall picture of ULS spasticity-related health status

    Time frame: through study completion, an average of 14 months

  26. Change from baseline in SQoL-6D pain/discomfort subscore

    Patient's Spasticity-Related Health Status (PS-RHS); The SQoL-6D consists of a 6-dimensions self-administered questionnaire that provides an overall picture of ULS spasticity-related health status

    Time frame: through study completion, an average of 14 months

  27. Number and percentage of patients with the following concomitant medications: oral antispasticity medications, pain medications (nociceptive and neuropathic pain), psychotropic drugs and anticoagulant drugs.

    Concomitant Medications, Non-Drug Therapies and Surgeries

    Time frame: Up to 14 months

  28. Number and percentage of patients with the following concomitant non-drug therapies for the management of ULS: physiotherapy and use of orthoses;

    Concomitant Medications, Non-Drug Therapies and Surgeries

    Time frame: Up to 14 months

  29. Number and percentage of patients with concomitant surgical procedures impacting caregivers' burden and patients' health.

    Concomitant Medications, Non-Drug Therapies and Surgeries

    Time frame: Up to 14 months

07

Study locations

27 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Feb 7, 2024
StartActual
Nov 16, 2023
Primary completionEst.
Feb 28, 2027
CompletionEst.
Feb 28, 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06245772
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 7, 2024
Start date
Nov 16, 2023
Primary completion
Feb 28, 2027 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion